Billiontoone (NASDAQ:BLLN) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Billiontoone (NASDAQ:BLLN) in a report released on Monday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $150.00 price objective on the stock.

Several other brokerages have also recently issued reports on BLLN. Wall Street Zen raised shares of Billiontoone to a “hold” rating in a research report on Saturday, November 15th. Piper Sandler started coverage on shares of Billiontoone in a report on Monday. They set an “overweight” rating and a $150.00 target price on the stock. William Blair started coverage on shares of Billiontoone in a research note on Monday. They issued an “outperform” rating for the company. Stifel Nicolaus assumed coverage on Billiontoone in a research note on Monday. They issued a “buy” rating and a $145.00 price objective on the stock. Finally, Wells Fargo & Company started coverage on Billiontoone in a report on Monday. They issued an “equal weight” rating and a $110.00 target price for the company. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.67.

Billiontoone Trading Down 10.6%

BLLN opened at $102.76 on Monday. Billiontoone has a 12-month low of $88.00 and a 12-month high of $138.70.

Billiontoone Company Profile

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.